Tonix Pharmaceuticals Holding Corp. (TNXP)
TNXP Stock Price Chart
Explore Tonix Pharmaceuticals Holding Corp. interactive price chart. Choose custom timeframes to analyze TNXP price movements and trends.
TNXP Company Profile
Discover essential business fundamentals and corporate details for Tonix Pharmaceuticals Holding Corp. (TNXP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 May 2012
Employees
81.00
Website
https://www.tonixpharma.comCEO
Seth Lederman
Description
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
TNXP Financial Timeline
Browse a chronological timeline of Tonix Pharmaceuticals Holding Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$3.59, while revenue estimate is $2.10M.
Earnings released on 11 Aug 2025
EPS came in at -$3.86 falling short of the estimated -$3.10 by -24.52%, while revenue for the quarter reached $2.00M , missing expectations by -17.89%.
Earnings released on 12 May 2025
EPS came in at -$2.84 surpassing the estimated -$3.23 by +12.07%, while revenue for the quarter reached $2.43M , missing expectations by -8.34%.
Earnings released on 18 Mar 2025
EPS came in at -$9.77 falling short of the estimated -$6.23 by -56.82%, while revenue for the quarter reached $2.58M , missing expectations by -19.31%.
Stock split effective on 5 Feb 2025
Shares were split 1 : 100 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Nov 2024
EPS came in at -$23.00 surpassing the estimated -$203.00 by +88.67%, while revenue for the quarter reached $2.82M , missing expectations by -17.00%.
Earnings released on 16 Aug 2024
EPS came in at -$1.93K falling short of the estimated -$991.00 by -94.55%, while revenue for the quarter reached $2.21M , missing expectations by -38.32%.
Stock split effective on 10 Jun 2024
Shares were split 1 : 32 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 Apr 2024
EPS came in at -$2.75K surpassing the estimated -$4.98K by +44.87%, while revenue for the quarter reached $2.48M , missing expectations by -34.68%.
Earnings released on 25 Mar 2024
EPS came in at -$0.86 surpassing the estimated -$1.64 by +47.56%, while revenue for the quarter reached $3.78M , missing expectations by -1.33%.
Earnings released on 9 Nov 2023
EPS came in at -$5.85K falling short of the estimated -$4.76K by -22.82%, while revenue for the quarter reached $3.99M , missing expectations by -22.24%.
Earnings released on 10 Aug 2023
EPS came in at -$8.56K surpassing the estimated -$8.88K by +3.60%.
Stock split effective on 10 May 2023
Shares were split 4 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2023
EPS came in at -$10.38K falling short of the estimated -$7.99K by -30.00%, while revenue for the quarter reached $33.90M .
Earnings released on 13 Mar 2023
EPS came in at -$11.18K surpassing the estimated -$12.58K by +11.11%.
Earnings released on 7 Nov 2022
EPS came in at -$13.78K surpassing the estimated -$14.38K by +4.17%.
Earnings released on 8 Aug 2022
EPS came in at -$24.36K surpassing the estimated -$29.15K by +16.44%, while revenue for the quarter reached $9.03M .
Stock split effective on 17 May 2022
Shares were split 1 : 32 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2022
EPS came in at -$31.90K matching the estimated -$31.90K.
Earnings released on 14 Mar 2022
EPS came in at -$44.66K matching the estimated -$44.66K.
Earnings released on 8 Nov 2021
EPS came in at -$31.90K surpassing the estimated -$44.66K by +28.57%.
Earnings released on 9 Aug 2021
EPS came in at -$44.66K matching the estimated -$44.66K.
Earnings released on 10 May 2021
EPS came in at -$44.66K falling short of the estimated -$38.28K by -16.67%.
Earnings released on 15 Mar 2021
EPS came in at -$63.80K falling short of the estimated -$57.42K by -11.11%, while revenue for the quarter reached $2.91M .
Earnings released on 9 Nov 2020
EPS came in at -$57.42K surpassing the estimated -$70.18K by +18.18%.
TNXP Stock Performance
Access detailed TNXP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.